News and Press Releases
Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases
Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 8, 2026
Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates
Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2025
New Anthem from Girl Band Raises Awareness of Type1 Diabetes After Research Highlights Silent Struggle
Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the condition The song, “Rise Up,” shares their experiences of living with the condition...
Category: Other, Pharmaceutical
Posted: May 29, 2025
Clean Cells acquires Karyologic to accelerate expansionin US biologics market
8 April 2025 -- Montaigu-Vendée, near Nantes, France -- Clean Cells, part of the Clean Biologics group, a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, today...
Category: BioManufacturing, Other, Pharmaceutical
Posted: April 8, 2025
4 Rue Nicolas Sadi Carnot ZA le Point du Jour 85600 MONTAIGU – VENDÉE FRANC
Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company
The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows selection of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025
100 Northern Avenue Boston Massachusetts 02210, United States
UK’s MHRA grants Promising Innovative Medicine designation to argenx’ investigational therapy, subcutaneous efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)
28 November 2024 -- Gerrards Cross, UK -- argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, confirmed today that its investigational...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 28, 2024
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878
Transition into clinical-stage development marks a significant corporate and R&D milestone 17 October 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024
Novartis Kisqali shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease Results remain consistent across secondary endpoints, including...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 16, 2024
SciRhom Secures €63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
The upsized and oversubscribed Series A financing round will be used to drive the lead development programme toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2...
Category: Drug Discovery, Other, Pharmaceutical
Posted: July 9, 2024
SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases
12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
Swixx Biopharma Expands to Latin America Through a Strategic Acquisition and Combination with Biopas
With the addition of $220m in sales, over 300 employees and therapeutic coverage in Neurology, Oncology, Immunology, Gastroenterology, Rare Diseases and Specialty, acquisition extends and transforms Swixx BioPharma’s footprint The...
Category: Other, Pharmaceutical
Posted: May 22, 2024
Myonex Closes Creapharm Acquisition Expanding Global Services
2 May 2024 -- Pennsylvania, US -- Myonex has completed the previously announced acquisition of Creapharm’s pharmaceutical services business. This transaction combines capabilities and flexibility to serve pharmaceutical and biotech...
Category: Biotechnology, Pharmaceutical
Posted: May 2, 2024
Myonex Announces Acquisition of Safeway Compounding Pharmacy to Expand its Clinical Trial Services Across the US
9 April 2024 -- Horsham, US -- Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, US. The pharmacy will operate as...
Category: Clinical Trials
Posted: April 9, 2024
